qsymia
qsymia: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| VIVUS INC (VVUS) | Approved |
FDA Decisions
Frequently asked questions
Who is developing qsymia?
qsymia is being developed by VIVUS INC.
What is qsymia's latest FDA decision?
The most recent tracked FDA decision for qsymia is Approval for 1 INDICATIONS AND USAGE QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and incr, dated July 17, 2012.
Get deeper analysis on qsymia
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis